About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is a company based in Washington (United States) founded in 2010 by Geoffrey Dow. 60 Degrees Pharmaceuticals has raised $1.76 million across 2 funding rounds. The company has 3 employees as of December 31, 2024. 60 Degrees Pharmaceuticals offers products and services including Malaria Medicine, Dengue Fever Treatment, Babesiosis Medicine, and Fungal Diseases Product. 60 Degrees Pharmaceuticals operates in a competitive market with competitors including Jaguar Health, Vyera Pharmaceuticals, ACE Pharmaceuticals, Artemis Therapeutics and Travelan, among others.
- Headquarter Washington, United States
- Employees 3 as on 31 Dec, 2024
- Founders Geoffrey Dow
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 60 Degrees Pharmaceuticals, Inc
-
Annual Revenue
$681.35 K (USD)168.7as on Dec 31, 2024
-
Net Profit
-$7.95 M (USD)-114.57as on Dec 31, 2024
-
EBITDA
-$9.65 M (USD)-90.95as on Dec 31, 2024
-
Total Equity Funding
$1.76 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
3
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SXTP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals offers a comprehensive portfolio of products and services, including Malaria Medicine, Dengue Fever Treatment, Babesiosis Medicine, and Fungal Diseases Product.
Prevents and treats malaria through innovative lifecycle disruption.
Addresses dengue infections to meet global medical needs.
Develops treatments for babesiosis and related parasitic diseases.
Targets fungal infections via research-based therapies.
Funding Insights of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals has successfully raised a total of $1.76M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by 60 Degrees Pharmaceuticals
Investment portfolio details for 60 Degrees Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 60 Degrees Pharmaceuticals
Detailed financials for 60 Degrees Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
60 Degrees Pharmaceuticals Comparisons
Peer comparison for 60 Degrees Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jaguar Health, Vyera Pharmaceuticals, ACE Pharmaceuticals, Artemis Therapeutics and Travelan, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel gastrointestinal products for humans and animals are developed sustainably.
|
|
| Locked | Locked | Locked |
Delivers comprehensive small molecule therapeutics for toxoplasmosis and neglected parasitic infections.
|
|
| Locked | Locked | Locked |
Drugs are manufactured for sister companies in the Netherlands.
|
|
| Locked | Locked | Locked |
Cameo provides tools for strain design in metabolic engineering projects.
|
|
| Locked | Locked | Locked |
Develops and commercializes antibodies for preventing gastrointestinal infections during travel.
|
Detailed competitors of 60 Degrees Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 60 Degrees Pharmaceuticals
Complete news archive for 60 Degrees Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals was founded in 2010 and raised its 1st funding round 13 years after it was founded.
60 Degrees Pharmaceuticals is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
Geoffrey Dow is the current CEO of 60 Degrees Pharmaceuticals. They have also founded this company.
60 Degrees Pharmaceuticals is a funded company, having raised a total of $1.76M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at 60 Degrees Pharmaceuticals is 3.
Annual revenue of 60 Degrees Pharmaceuticals is $681.35K as on Dec 31, 2024.
Founded in 2010, 60 Degrees Pharmaceuticals operates in the biopharmaceutical sector, focusing on the discovery and development of treatments for tropical diseases such as dengue and malaria. The pipeline includes 60P001, an alpha-glucosidase inhibitor, and 60P002, a platelet activating factor receptor antagonist, both in Phase 1b for dengue fever. Preparations are underway for the 2018 commercial launch of 60P003 for malaria prevention, following a U.S. Army agreement.
60 Degrees Pharmaceuticals's top competitors include Jaguar Health, ACE Pharmaceuticals and MalarVx.
60 Degrees Pharmaceuticals offers Malaria Medicine, Dengue Fever Treatment, Babesiosis Medicine, and Fungal Diseases Product.
Yes, 60 Degrees Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol SXTP.
The ticker symbol of 60 Degrees Pharmaceuticals is SXTP on NASDAQ.